SCOTTSDALE, Ariz., Dec. 14 /PRNewswire-FirstCall/ -- Motion DNA Corporation announced that the company continues to work towards completing a new version of its BioCap(TM) Software scheduled to be released later this month. Pending the filing of patents related to the new version, Motion DNA is forced to delay the distributor training until such applications have been filed by the company's attorneys.
Once the attorneys have completed and filed the appropriate patent applications, the software is expected to be released and more details regarding the applications shall be made available to the public.
"It was important for us to provide some protections for this newest version of our software since it does something that none of our competitors have been able to implement," said Zig Ziegler, President and CEO of Motion DNA. "We believe our products to be the best software in our market, these improvements move us 10 years ahead."
As a result of the delay in patent filings, the attorneys have requested Motion DNA delay its distributor training until the applications have been filed. The company has received over 200 inquiries from individuals and companies requesting distribution rights around the United States, Canada, and Europe. The patent applications are expected to be filed no later than December 30, 2005.
The patent applications are being filed by attorneys representing the company from Greenburg-Traurig, LLP of Phoenix. The company is also expected to provide an update on pending contracts with customers in January as it works to finalize agreements.
About Motion DNA:
Motion DNA Corporation provides diagnostic testing for medical professionals and sports organizations. Motion DNA's biomechanical analyses and detailed reports provide its customers and consumers with solutions for preventing injuries, identifying physical limitations, diagnosing pre-existing injuries related to biomechanics, and improving physical performance levels.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors. The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.
Mr. Zig Ziegler, President
AGORA Investor Relations
Motion DNA Corporation
CONTACT: Corporate Inquiries, Mr. Zig Ziegler, President of Motion DNACorporation, +1-480-425-7734, firstname.lastname@example.org; or InvestorRelations, AGORA Investor Relations, MTDX@Agoracom.com, for Motion DNACorporation